Swiss National Bank Has $144.09 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Swiss National Bank reduced its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 259,600 shares of the company’s stock after selling 7,500 shares during the period. Swiss National Bank owned 0.31% of IDEXX Laboratories worth $144,091,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Patron Partners LLC grew its stake in IDEXX Laboratories by 2.7% in the 4th quarter. Patron Partners LLC now owns 765 shares of the company’s stock valued at $425,000 after buying an additional 20 shares during the last quarter. NewEdge Wealth LLC boosted its stake in IDEXX Laboratories by 3.1% in the 4th quarter. NewEdge Wealth LLC now owns 659 shares of the company’s stock valued at $366,000 after purchasing an additional 20 shares during the period. Phoenix Holdings Ltd. grew its stake in shares of IDEXX Laboratories by 2.8% in the third quarter. Phoenix Holdings Ltd. now owns 769 shares of the company’s stock valued at $338,000 after acquiring an additional 21 shares in the last quarter. BluePath Capital Management LLC grew its position in shares of IDEXX Laboratories by 1.8% during the 4th quarter. BluePath Capital Management LLC now owns 1,197 shares of the company’s stock worth $663,000 after purchasing an additional 21 shares in the last quarter. Finally, Valley National Advisers Inc. increased its stake in IDEXX Laboratories by 84.6% during the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock worth $26,000 after acquiring an additional 22 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, SVP George Fennell sold 8,198 shares of the business’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the sale, the senior vice president now owns 6,712 shares in the company, valued at approximately $3,851,815.44. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other news, SVP George Fennell sold 8,198 shares of IDEXX Laboratories stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the sale, the senior vice president now directly owns 6,712 shares in the company, valued at $3,851,815.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jonathan Jay Mazelsky sold 12,000 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the completion of the sale, the chief executive officer now owns 79,247 shares of the company’s stock, valued at $45,377,624.67. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 43,524 shares of company stock worth $24,871,960. Corporate insiders own 2.11% of the company’s stock.

Wall Street Analysts Forecast Growth

IDXX has been the topic of a number of recent research reports. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Thursday. Piper Sandler lowered IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 target price on the stock. in a research report on Tuesday, January 30th. William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. The Goldman Sachs Group increased their price target on IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. Finally, Barclays cut their price target on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a report on Thursday. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $580.88.

IDEXX Laboratories Stock Up 1.0 %

Shares of NASDAQ IDXX opened at $480.60 on Friday. The company has a quick ratio of 1.17, a current ratio of 1.57 and a debt-to-equity ratio of 0.40. IDEXX Laboratories, Inc. has a 52 week low of $372.50 and a 52 week high of $583.39. The firm’s fifty day moving average is $525.21 and its 200 day moving average is $512.07. The company has a market cap of $39.69 billion, a price-to-earnings ratio of 46.52, a PEG ratio of 3.74 and a beta of 1.27.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, February 5th. The company reported $2.32 EPS for the quarter, topping the consensus estimate of $2.12 by $0.20. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. The company had revenue of $901.60 million for the quarter, compared to the consensus estimate of $891.88 million. During the same period in the previous year, the firm earned $2.05 earnings per share. The firm’s revenue for the quarter was up 8.8% on a year-over-year basis. On average, equities research analysts expect that IDEXX Laboratories, Inc. will post 11.06 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.